PPADS (tetrasodium)

PPADS (tetrasodium)

• CAS Number: 192575-19-2
• UNSPSC Description: PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca2+ exchanger in guinea pig airway smooth muscle[1][2].
• Target Antigen: Na+/Ca2+ Exchanger; P2X Receptor
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/ppads-tetrasodium.html
• Purity: 95.0
• Solubility: H2O : 50 mg/mL (ultrasonic)
• Smiles: O=S(C1=CC=C(/N=N/C2=NC(C)=C(O)C(C=O)=C2COP(O[Na])(O[Na])=O)C(S(=O)(O[Na])=O)=C1)(O[Na])=O
• Molecular Weight: 599.30
• References & Citations: [1]Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674(2-3):439-44.|[2]Huo H, et al. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J Biol Chem. 2018 Aug 17;293(33):12820-12831.|[3]Einfluss von ATP und seinen Derivaten auf die Aktivierung von Monozyten.|[4]Rost S, et al. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangialproliferative glomerulonephritis. Kidney Int. 2002 Nov;62(5):1659-71.bioRxiv. 2024 November 03.|J Biol Chem. 2021 Sep 3;101166.|Mil Med Res. 2024 Jun 27;11(1):41.|bioRxiv. 2023 Sep 17.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported